Matinas Biopharma Holdings, Inc. (MTNB) Stock

About Matinas Biopharma Holdings, Inc.

Matinas Biopharma Holdings, Inc. is led by CEO Jerome D. Jabbour, employs 3 people, headquartered in US, publicly traded since 2014.

Matinas Biopharma Holdings, Inc. (MTNB) stock trades at $1.70 with a market capitalization of $726291. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.15, reflecting a net loss over the last twelve months, price-to-book of 0.63, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.52 and $29.55, and currently trades 94.2% below its 52-week high.

On profitability, Matinas Biopharma Holdings, Inc. generates a return on equity (ROE) of -181.45% (negative, reflecting a net loss), return on capital employed of -323.38%.

Matinas Biopharma Holdings, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Matinas Biopharma Holdings, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-10.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-7.0M.

Borrowings stand at $1.0M, cash from operations was $-7.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -144.4% over five years, and was -200.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Matinas Biopharma Holdings, Inc. (MTNB) — frequently asked questions